These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 23817186)

  • 1. Reply: Optimal renin-angiotensin-aldosterone system blockade--wish fulfilled.
    Nussberger J; Bohlender J
    Nat Rev Cardiol; 2013 Aug; 10(8):486. PubMed ID: 23817186
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimal renin-angiotensin system blockade-wishful thinking?
    Makani H; Bangalore S; Messerli FH
    Nat Rev Cardiol; 2013 Aug; 10(8):486. PubMed ID: 23817190
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacotherapy: Optimal blockade of the renin-angiotensin-aldosterone system.
    Nussberger J; Bohlender J
    Nat Rev Cardiol; 2013 Apr; 10(4):183-4. PubMed ID: 23478259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Debate concerning the optimal blockage of the renin-angiotensin system].
    Choukroun G
    Nephrol Ther; 2010 Jan; 6 Spec No 1():H1-9. PubMed ID: 20129454
    [No Abstract]   [Full Text] [Related]  

  • 5. The evolution of renin-angiotensin blockade: angiotensin-converting enzyme inhibitors as the starting point.
    Sica DA
    Curr Hypertens Rep; 2010 Apr; 12(2):67-73. PubMed ID: 20424943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted?
    Mansur SJ; Hage FG; Oparil S
    Curr Cardiol Rep; 2010 Nov; 12(6):450-63. PubMed ID: 20827517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
    Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
    J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [How I treat... by optimizing the blockade of the renin-angiotensin-aldosterone system].
    Schleich F; Krzesinski JM; Piérard L; Scheen AJ
    Rev Med Liege; 2008 Apr; 63(4):174-81. PubMed ID: 18575070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
    Krum H; Gilbert RE
    J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
    Middeke M
    Dtsch Med Wochenschr; 2012 Nov; 137(48):2498. PubMed ID: 23168983
    [No Abstract]   [Full Text] [Related]  

  • 11. [Dual blockade of the renin-angiotensin system in hypertensive treatment: no].
    van der Giet M
    Dtsch Med Wochenschr; 2012 Nov; 137(48):2499. PubMed ID: 23168984
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative role of angiotensin receptor blockers versus other agents in the management of hypertension, cardiovascular disease and nephropathy.
    Tempelhof MW
    South Med J; 2009 Dec; 102(12):1201-2. PubMed ID: 20016423
    [No Abstract]   [Full Text] [Related]  

  • 13. Renin inhibition--benefit beyond hypertension control.
    Kher V
    J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
    Gerc V; Buksa M; Loza V; Kulic M
    Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in the clinical effects of angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers: a critical review of the evidence.
    Dézsi CA
    Am J Cardiovasc Drugs; 2014 Jun; 14(3):167-73. PubMed ID: 24385234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin inhibitors in chronic heart failure: the Aliskiren Observation of Heart Failure Treatment study in context.
    Krum H; Maggioni A
    Clin Cardiol; 2010 Sep; 33(9):536-41. PubMed ID: 20842736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of the renin angiotensin system: proven benefits, unproven safety.
    Parfrey PS
    Ann Intern Med; 2008 Jan; 148(1):76-7. PubMed ID: 17984483
    [No Abstract]   [Full Text] [Related]  

  • 20. Renin-angiotensin-aldosterone system (RAAS) pharmacogenomics: implications in heart failure management.
    Beitelshees AL; Zineh I
    Heart Fail Rev; 2010 May; 15(3):209-17. PubMed ID: 18351457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.